BCRX BIOCRYST PHARMACEUTICALS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 882796 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY60.3%
TTM net income YoY-3,996.8%
TTM EPS YoY-2,460.0%
Revenue 3-yr CAGR44.7%
Net income 3-yr CAGR—
Margins
Gross margin97.9%
Operating margin-30.1%
Net margin-37.4%
FCF margin38.0%
EBITDA margin-29.9%
Returns
ROE—
ROA-69.3%
ROIC (approx.)—
Asset turnover1.85x
Leverage & solvency
Liabilities / assets167.2%
Debt / equity—
Current ratio2.71x
Interest coverage-3.77x
Cash quality & payout
Operating cash flow / net income-1.02x
Accruals ratio-140.2%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $180.29M | $218.25M | $156.41M | $406.56M | $159.40M | $163.35M | $145.53M | $131.53M |
| Cost of revenue | $1.57M | $3.84M | $5.38M | $9.52M | $2.19M | $2.80M | $4.57M | $6.09M |
| Gross profit | $178.72M | $214.41M | $151.04M | $397.03M | $157.21M | $160.56M | $140.97M | $125.44M |
| R&D expense | $58.21M | $51.97M | $60.32M | $40.87M | $44.60M | $43.39M | $37.27M | $49.44M |
| SG&A expense | $67.17M | $63.98M | $94.55M | $95.78M | $83.01M | $87.38M | $82.47M | $80.51M |
| Operating income | $53.33M | $98.47M | -$701.60M | $260.38M | $29.59M | $29.79M | $21.23M | -$4.51M |
| Interest expense | $21.18M | $21.71M | $19.78M | $14.13M | $19.66M | $21.58M | $23.49M | $24.45M |
| Pretax income | $38.59M | $79.47M | -$720.81M | $248.02M | $12.13M | $6.49M | $758,000 | -$25.99M |
| Income tax | $669,000 | $1.08M | $1.00M | $2.17M | -$769,000 | $1.40M | $726,000 | $804,000 |
| Net income | $37.92M | $78.39M | -$721.81M | $245.84M | $12.90M | $5.08M | $32,000 | -$26.80M |
| EBITDA | $53.57M | $98.98M | -$701.14M | $260.78M | $29.93M | $30.11M | $21.56M | -$4.20M |
| EPS (basic) | 0.15 | 0.31 | -2.98 | — | 0.06 | 0.02 | 0.00 | — |
| EPS (diluted) | 0.14 | 0.30 | -2.98 | — | 0.06 | 0.02 | 0.00 | — |
| Weighted avg. shares (diluted) | 267.62M | 265.17M | 242.26M | — | 219.88M | 219.89M | 215.26M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $96.97M | $154.97M | $171.59M | $89.74M | $84.08M | $88.03M | $105.19M | $106.32M |
| Short-term investments | $278.03M | $197.60M | $66.81M | $185.01M | $128.79M | $172.00M | $189.90M | $216.14M |
| Receivables | $121.79M | $110.76M | $109.27M | $106.82M | $91.33M | $91.18M | $93.39M | $79.07M |
| Inventory | $13.74M | $6.06M | $5.99M | $5.40M | $5.23M | $5.04M | $6.87M | $8.09M |
| Current assets | $531.15M | $484.68M | $373.62M | $404.35M | $355.68M | $398.46M | $409.98M | $421.97M |
| PP&E, net | $1.66M | $9.06M | $9.37M | $8.78M | $8.40M | $8.46M | $7.59M | $7.78M |
| Total assets | $591.07M | $557.85M | $465.05M | $514.16M | $446.42M | $457.19M | $480.05M | $490.42M |
| Current liabilities | $195.83M | $208.85M | $195.39M | $196.07M | $190.24M | $177.16M | $139.85M | $160.38M |
| Long-term debt | $395.61M | $395.40M | $395.20M | $0 | $194.37M | $242.79M | $315.41M | $314.87M |
| Total debt | $395.61M | $395.40M | $395.20M | $0 | $194.37M | $242.79M | $315.41M | $314.87M |
| Total liabilities | $988.45M | $1.01B | $1.02B | $633.31M | $834.31M | $878.78M | $931.97M | $966.35M |
| Shareholders' equity | -$397.38M | -$454.29M | -$553.84M | -$119.15M | -$387.89M | -$421.59M | -$451.93M | -$475.93M |
| Net debt | $298.64M | $240.43M | $223.61M | -$89.74M | $110.29M | $154.76M | $210.22M | $208.55M |
| Shares outstanding | 256.12M | 255.26M | 254.01M | 213.06M | 210.52M | 209.91M | 209.21M | 208.54M |
| Cash flow statement | ||||||||
| Operating cash flow | $32.98M | $104.34M | -$61.79M | $291.96M | $41.62M | $41.30M | -$27.52M | -$5.21M |
| Capital expenditure | $233,000 | $209,000 | $403,000 | $802,000 | $1.34M | $179,000 | $143,000 | $675,000 |
| Free cash flow | $32.75M | $104.13M | -$62.19M | $291.16M | $40.28M | $41.12M | -$27.66M | -$5.89M |
| Investing cash flow | -$78.88M | -$110.15M | -$268.65M | -$83.49M | $13.57M | $29.13M | $27.09M | $17.80M |
| Financing cash flow | -$12.08M | -$11.15M | $412.55M | -$217.96M | -$58.81M | -$73.69M | $529,000 | -$4.02M |
| Depreciation & amortization | $244,000 | $513,000 | $461,000 | $394,000 | $335,000 | $329,000 | $331,000 | $309,000 |
| Stock-based compensation | $14.24M | $14.69M | $16.03M | $23.79M | $18.60M | $21.30M | $21.37M | $21.34M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.